About BillionToOne, Inc.
https://www.billiontoone.comBillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection.
CEO
Oguzhan Atay
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Medical - Diagnostics & Research
Sector Healthcare
Went public November 6, 2025
Method of going public IPO
Full time employees 620
ETFs Holding This Stock
Summary
Total 22
Showing Top 3 of 22
Ratings Snapshot
Rating : D+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Most Recent Analyst Grades
Grade Summary
Buy 1
Overweight 1
Showing Top 2 of 2
Price Target
Target High $160
Target Low $110
Target Median $132.5
Target Consensus $133.67
Market Cap $4.01 B
52w High $138.70
52w Low $80.51
P/E -387.28
Volume 160.51K
Outstanding Shares 45.77M
About BillionToOne, Inc.
https://www.billiontoone.comBillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $83.52M ▲ | $48.78M ▲ | $1.51M ▲ | 1.8% ▲ | $0.03 ▲ | $8.55M ▲ |
| Q2-2025 | $66.57M ▲ | $45.09M ▲ | $-246K ▲ | -0.37% ▲ | $-0.01 ▲ | $1.55M ▲ |
| Q1-2025 | $58.96M ▲ | $40.29M ▲ | $-3.99M ▲ | -6.76% ▲ | $-0.09 ▲ | $-2.06M ▲ |
| Q4-2024 | $45.08M ▲ | $37.41M ▲ | $-11.48M ▲ | -25.46% ▲ | $-0.26 ▲ | $-9.61M ▲ |
| Q3-2024 | $38.42M | $32.85M | $-14.9M | -38.79% | $-0.33 | $-12.67M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $195.15M ▲ | $327.52M ▲ | $147.63M ▲ | $179.9M ▲ |
| Q2-2025 | $188.96M ▼ | $312.63M ▲ | $143.48M ▲ | $169.16M ▲ |
| Q4-2024 | $191.48M | $302.06M | $134.31M | $167.75M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $5.71M ▲ | $10M ▲ | $-2.12M ▲ | $-1.68M ▼ | $6.19M ▲ | $7.87M ▲ |
| Q2-2025 | $-2.12M | $1.9M | $-2.61M | $-552.5K | $0 | $-707K |
| Q1-2025 | $-2.12M ▲ | $1.9M ▲ | $-2.61M ▼ | $-552.5K ▼ | $0 ▲ | $-707K ▲ |
| Q4-2024 | $-11.48M | $-8.42M | $-2.1M | $-288K | $-10.82M | $-10.53M |
CEO
Oguzhan Atay
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Medical - Diagnostics & Research
Sector Healthcare
Went public November 6, 2025
Method of going public IPO
Full time employees 620
ETFs Holding This Stock
Summary
Total 22
Showing Top 3 of 22
Ratings Snapshot
Rating : D+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Most Recent Analyst Grades
Grade Summary
Buy 1
Overweight 1
Showing Top 2 of 2
Price Target
Target High $160
Target Low $110
Target Median $132.5
Target Consensus $133.67